Annual Report along with notice of AGM for the year ended March,2025.
ALPA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alpa Laboratories Limited has submitted the Notice of its 37th AGM and the Annual Report for FY 2024-25, with the AGM scheduled for Monday, 29th September 2025 at 2:00 PM via video conferencing. The Indore-based pharmaceutical company reported standalone sales and other income of ₹13,575.71 lakhs (up from ₹12,361.28 lakhs in FY24) and net profit of ₹1,982.90 lakhs (up from ₹1,685.92 lakhs in FY24), reflecting roughly 17.6% profit growth year-on-year. Key AGM items include adoption of audited financial statements, re-appointment of Mr. Shitul Shah as director by rotation, ratification of cost auditor remuneration at ₹70,000, and appointment of M/s Shilpesh Dalal & Co. as secretarial auditor for a five-year term (FY 2025-26 to FY 2029-30). A special resolution seeks shareholder approval for giving loans, guarantees, or making investments up to ₹160 crores, exceeding the standard Section 186 limits. E-voting will be facilitated through CDSL with a cut-off date of 22nd September 2025.
This is a routine annual filing with no immediate material impact on shareholders, though it confirms healthy profit growth and a sharper decline in finance costs. The proposed ₹160 crore limit for loans/investments/guarantees indicates room for future expansion or strategic deployment of capital, which shareholders should monitor.